Catalent Inc (NYSE:CTLT) has received a consensus recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $50.50.
A number of analysts have recently commented on CTLT shares. TheStreet upgraded Catalent from a “c” rating to a “b-” rating in a report on Wednesday, February 6th. UBS Group upgraded Catalent from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $43.00 to $54.00 in a report on Tuesday. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Wednesday, February 6th. Finally, Jefferies Financial Group upped their price objective on Catalent from $44.00 to $50.00 and gave the stock a “hold” rating in a report on Tuesday.
In related news, SVP Lance Miyamoto sold 43,619 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $42.49, for a total value of $1,853,371.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Aristippos Gennadios sold 3,392 shares of the stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $42.18, for a total value of $143,074.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,326 shares of company stock valued at $2,303,676. Insiders own 1.40% of the company’s stock.
Shares of Catalent stock traded up $0.19 during trading hours on Wednesday, reaching $42.75. 1,499,363 shares of the company’s stock were exchanged, compared to its average volume of 888,686. Catalent has a 52-week low of $29.23 and a 52-week high of $46.43. The firm has a market cap of $6.47 billion, a PE ratio of 26.89, a P/E/G ratio of 2.43 and a beta of 1.69. The company has a quick ratio of 1.63, a current ratio of 2.08 and a debt-to-equity ratio of 1.36.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.08. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The company had revenue of $623.00 million for the quarter, compared to analyst estimates of $608.38 million. During the same quarter in the prior year, the company posted $0.45 EPS. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. Equities research analysts anticipate that Catalent will post 1.69 EPS for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.